PARIS May 17 French drugmaker Sanofi
said a late-stage Phase III trial of a drug designed to treat
myelofibrosis led to positive results.
Myelofibrosis is a rare, life-threatening condition that
involves abnormal blood cell production and scarring in the bone
"Patients with myelofibrosis in advanced stages are
desperately ill and in need of treatments that will improve
their outcomes," Debasish Roychowdhury, head of Sanofi Oncology,
said in a statement on Friday.
"Now we are planning regulatory filings with authorities to
make this medicine available for patients."
Rare disease treatments are among Sanofi's key focuses
following the acquisition of U.S. biotech Genzyme as its sales
are hit by generic competition and European austerity measures.
(Reporting by James Regan; Editing by David Cowell)